natgillin/translations-raw huggingface dataset:
The method of any one of claims 1 to 3, further comprising passing the buffer solution of the monomeric platinum pyrophosphate complex through an inline filter comprising a filter medium to remove any undissolved solids to obtain a clear filtrate solution prior to said recrystallizing. 
Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time da nadalje sadrži prolaz puferske otopine monomernog kompleksa platina pirofosfata kroz protočni (inline) filter koji sadrži medij za filtriranje radi uklanjanja nerastopljenih krutina kako bi se dobila bistra otopina filtrata prije spomenute rekristalizacije.
The method of claim 5, wherein said clear filtrate solution is circulated back to the vessel for dissolving the monomeric platinum pyrophosphate complex until all the buffer solution of the monomeric platinum pyrophosphate complex becomes clear, wherein optionally the filter medium comprises activated carbon. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time da navedena bistra otopina filtrata cirkulira natrag u posudu za otapanje monomernog kompleksa platina pirofosfata dok sva puferska otopina monomernog kompleksa platina pirofosfata ne postane bistra, pri čemu po izboru medij za filtriranje sadrži aktivni ugljen
The method of any one of claims 1 to 10, wherein the isolated monomeric platinum pyrophosphate complex has a purity of at least 96.0% (w/w) or at least 98.0% (w/w). 
Postupak prema bilo kojem od zahtjeva 1 do 10, naznačen time da izolirani monomerni kompleks platina pirofosfata ima čistoću od najmanje 96.0% (w/w) ili najmanje 98.0% (w/w).
a communication interface configured to receive the first user data from a wireless device via radio network equipment and to forward the second and third user data to the radio network equipment for transmission to the wireless device, wherein the wireless device comprises radio-frequency circuitry and processing circuitry operatively connected to the radio-frequency circuitry, wherein the processing circuitry of the wireless device is configured to: 
slanje konfiguracije u bežični uređaj koja ukazuje na vezani komplet radio resursa u kojem je bežični uređaj konfiguriran samo za rad. Bežični uređaj, koji sadrži radiofrekventno sklopovlje i sklopovlje za obradu radno spojeno s radiofrekventnim sklopovljem, gdje bežični uređaj može tako raditi da komunicira s opremom za radio mrežu u mreži za bežične komunikacije, gdje je sklopovlje za obradu konfigurirano za:
A compound of the formula (I) or a salt thereof: (in the formula, 
Spoj sa formulom (I) ili njegova sol: u formuli,
is phenyl which may be substituted; or 
je fenil koji može biti supstituiran; ili
and R6 may form a benzene ring which may be substituted, together with carbon atoms to which they are bonded; and 
i R6 mogu formirati benzenov prsten koji može biti supstituiran, zajedno sa atomima ugljika za koje su oni vezani; i
is a single bond or a double bond; and the term "lower" refers to 1 to 6 carbon atoms. 
je jednostruka veza ili dvostruka veza; i termin "niži" odnosi se na 1 do 6 ugljikovih atoma.
The compound or a salt thereof according to claim 1, wherein R5 is H, and R6 is phenyl which may be substituted. 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 1, gdje R5 je H, i R6 je fenil koji može biti supstituiran.
The compound or a salt thereof according to claim 2, wherein ---- is a single bond. 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 2, gdje ---- je jednostruka veza.
The compound or a salt thereof according to claim 4, wherein R1 is H, R2 is H or halogen, and R3 is halogen. 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 4, gdje R1 je H, R2 je H ili halogen, i R3 je halogen.
The compound or a salt thereof according to claim 10, wherein the compound is selected from the group consisting of: 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 10, gdje spoj je odabran iz grupe koja se sastoji od:
The pharmaceutical composition according to claim 14, which is a pharmaceutical composition for use in preventing and/or treating cognitive impairment, schizophrenia negative symptom, cognitive impairment associated with schizophrenia (CIAS), Parkinson's disease, Alzheimer's disease, Huntington's disease, depression, attention deficit hyperactivity disorder (ADHD), or drug dependency. 
Farmaceutska kompozicija u skladu sa patentnim zahtjevom 14, koja je farmaceutska kompozicija za primjenu u prevenciji i/ili liječenju kognitivnog oštećenja, negativnog simptoma šizofrenije, kognitivnog oštećenja povezanog sa šizofrenijom (CIAS), Parkinsonove bolesti, Alzheimerove bolesti, Huntingtonove bolesti, depresije, hiperaktivnog poremećaja sa nedostatkom pažnje (ADHD), ili ovisnosti o lijekovima.
A nucleic acid molecule comprising in the 5' → 3' direction of transcription: 
Molekula nukleinske kiseline koja sadrži u 5' → 3' smjeru transkripcije:
The nucleic acid molecule as claimed in any one of claims 1 to 3, which is a closed circular molecule or a linear molecule. 
Molekula nukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1 do 3, koja je zatvorena cirkularna molekula ili linearna molekula.
The nucleic acid molecule as claimed in any one of claims 1 to 4, wherein the transcribable nucleic acid sequence comprises a nucleic acid sequence coding for a peptide or protein and the nucleic acid sequence for introducing a transcribable nucleic acid sequence is a multiple cloning site. 
Molekula nukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1 do 4, pri čemu transkriptabilna sekvenca nukleinske kiseline sadrži sekvencu nukleinske kiseline koja kodira peptid ili protein i sekvenca nukleinske kiseline za uvođenje transkriptabilne sekvence nukleinske kiseline je mjesto višestrukog kloniranja.
The nucleic acid molecule as claimed in any one of claims 1 to 5, further comprising one or more members selected from the group consisting of: (i) a reporter gene; (ii) a selectable marker; and (iii) an origin of replication. 
Molekula nukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1 do 5, koja dalje sadrži jedan ili više članova odabranih iz grupe koja se sastoji od: (i) reporterskog gena; (ii) odabirnog markera; i (iii) podrijetla replikacije.
The nucleic acid molecule as claimed in any one of claims 1 to 6, which is suitable, in particular after linearization, for in vitro transcription of RNA, in particular mRNA. 
Molekula nukleinske kiseline u skladu s bilo kojim od patentnih zahtjeva 1 do 6, koja je pogodna, posebno nakon linearizacije, za in vitro transkripciju RNK, posebno iRNK.
a 3'-untranslated region which is not naturally linked to the nucleic acid sequence (b), said 3'-untranslated region comprising 
3'-netranslatirajuću regiju koja nije prirodno povezana sa sekvencom nukleinske kiseline (b), navedena 3'-netranslatirajuća regija sadrži
The RNA as claimed in claim 9, further comprising (d) a nucleic acid sequence which is a polyadenyl sequence optionally comprising within the polyadenyl sequence a sequence of one or more consecutive nucleotides containing nucleotides other than A nucleotides, wherein, preferably, said nucleic acid sequence (d) is located at the 3' end of said RNA, and/or the nucleic acid sequences (c) and (d) are active so as to increase the translation efficiency and/or the stability of the nucleic acid sequence coding for a peptide or protein. 
RNK u skladu s patentnim zahtjevom 9, koja dalje sadrži (d) sekvencu nukleinske kiseline koja je poliadenilna sekvenca koja opcionalno sadrži unutar poliadenilne sekvence sekvencu jednog ili više uzastopnih nukleotida, koja sadrži nukleotide koji nisu nukleotidi A, pri čemu se, poželjno, navedena sekvenca nukleinske kiseline (d) nalazi na 3' kraju navedene RNK, i/ili su sekvence nukleinske kiseline (c) i (d) aktivne tako da povećavaju efikasnost translacije i/ili stabilnost sekvence nukleinske kiseline koja kodira peptid ili protein.
The RNA as claimed in claim 9 or 10, further comprising (e) a 5' Cap. 
RNK u skladu s patentnim zahtjevom 9 ili 10, koja dalje sadrži (e) 5' kapu.
obtaining RNA encoding the peptide or protein according to the method of claim 12, and translating the RNA. 
dobivanje RNK koja kodira peptid ili protein u skladu s postupkom u skladu s patentnim zahtjevom 12, i translaciju RNK.
The method as claimed in claim 12 or 13, characterized in that it further comprises, prior to transcription of the nucleic acid molecule, cleavage of the nucleic acid molecule. 
Postupak u skladu s patentnim zahtjevom 12 ili 13, naznačen time što dalje sadrži, prije transkripcije molekule nukleinske kiseline, cijepanje molekule nukleinske kiseline.
transcribing the nucleic acid obtained, said 3'-untranslated region comprising 
transkripciju dobivene nukleinske kiseline, gdje navedena 3'-netranslatirajuća regija sadrži
A method of obtaining a peptide or protein, comprising: obtaining RNA by the method of claim 15 or 16, and 
Postupak za dobivanje peptida ili proteina, koji sadrži: dobivanje RNK postupkom u skladu s patentnim zahtjevom 15 ili 16, i
The RNA as claimed in any one of claims 8 to 11 and 19 for use in a method of transfecting a host cell, wherein, preferably, the host cell is an antigen-presenting cell, in particular a dendritic cell, a monocyte or a macrophage. 
RNK u skladu s bilo kojim od patentnih zahtjeva 8 do 11 i 19 za uporabu u postupku za transfekciju stanice domaćina, pri čemu je, poželjno, stanica domaćin antigen-prezentirajuća stanica, posebno dendritična stanica, monocit ili makrofag.
The RNA as claimed in any one of claims 8 to 11 and 19 for use in a method of reprogramming somatic cells to cells having stem cell characteristics. 
RNK u skladu s bilo kojim od patentnih zahtjeva 8 do 11 i 19 za uporabu u postupku za reprogramiranje somatskih stanica u stanice koje imaju karakteristike matične stanice.
Anchor (1) according to claims 3 and 5, wherein the penetration tips (43) are located at a distal end of the girders (40). 
Sidro (1) prema zahtjevima 3 i 5, naznačeno time da su prodorni vrhovi (43) smješteni na udaljenom kraju nosača (40).
Anchor (1) according to claim 5 or 6, wherein the girders (40) extend parallel to the plane of symmetry (M) . 
Sidro (1) u skladu s patentnim zahtjevom 5 ili 6, naznačeno time što se nosači (40) pružaju paralelno s ravninom simetrije (M).
Anchor (1) according to any one of the preceding claims, wherein the fluke (10) comprises reinforcement plates (50, 55, 56, 57) below the penetration plates (11, 12) that are connected to each other along their edges to form a rigid hollow box. 
Sidro (1) u skladu s bilo kojim od prethodnih zahtjeva, naznačeno time što kuka sidra (10) sadrži potporne ploče (50, 55, 56, 57) ispod probojnih ploča (11, 12), koje su međusobno povezane duž njihovih rubova i tvore krutu šuplju kutiju.
A process for the isolation of salt of formula I, as defined in Claim 1 or Claim 2, which process comprises precipitation of the salt of formula I from a mixture of N-formyl-L-leucine, a compound of formula II, and a solvent for the compound of formula II. 
Postupak za izoliranje soli formule I, kako je definirano u zahtjevu 1 ili zahtjevu 2, gdje postupak obuhvaća taloženje soli formule I iz smjese N-formil-L-leucina, spoja formule II, i otapala spoja formule II.
the N-formyl-L-leucine has a percentage enantiomeric excess of the L-enantiomer of greater than 95%; and/or the process comprises the addition of N-formyl-L-leucine to a mixture of a compound of formula II and a solvent for the compound of formula II. 
N-formil-L-leucin ima postotak enantiomerskog viška L-enantiomera veći od 95%; i/ili postupak obuhvaća dodavanje N-formil-L-leucina u smjesu spoja formule II i otapala spoja formule II.
the solvent for the compound of formula II is one or more organic solvents selected from the group consisting of toluene, a xylene, ethylbenzene, an alkylbenzene, a halobenzene, a nitrobenzene, a methoxybenzene, 2-propanol, methylcyclohexane, a heptane, an alkenyl acetate and an alkyl acetate; 
otapalo za spoj formule II je jedan ili više organskih otapala izabranih iz grupe koja obuhvaća toluen, ksilen, etilbenzen, alkilbenzen, halobenzen, nitrobenzen, metoksibenzen, 2- propanol, metilcikloheksan, heptan, alkenil acetat i alkil acetat;
the solvent for the compound of formula II is isopropyl acetate, toluene or a mixture of isopropyl acetate and isopropanol; and/or the process is conducted at a temperature from 30°C to 80°C. 
otapalo za spoj formule II je izopropil acetat, toluen ili smjesa izopropil acetata i izopropanola; i/ili postupak se izvodi na temperaturi od 30°C do 80°C.
A process for preparing a compound of formula IIA, said process comprising the step of reacting a salt of formula I, as defined in Claim 1 or Claim 2, with a base. 
Postupak za pripremu spoja formule IIA, spomenuti postupak obuhvaća korak reagiranja soli formule I, definirane u zahtjevu 1 ili zahtjevu 2, s bazom.
A process for preparing a compound of formula IIA, as defined in Claim 8, said process comprising the steps of: 
Postupak za pripremu spoja formule IIA, kako je definirano u zahtjevu 8, spomenuti postupak obuhvaća korake:
A process for the preparation of Lacosamide (formula III): which process comprises either: 
Postupak za pripremu Lakozamida (formula III): postupak koji obuhvaća ili:
a process as defined in Claims 8 or Claim 9, followed by reaction of the compound of formula IIA with an acetyl donor. 
postupak kako je definirano u zahtjevu 8 ili zahtjevu 9, praćen reakcijom spoja formule IIA s acetil donorom.
A process according to Claim 10, wherein the acetyl donor is a branched or linear C2-8 1-alkenyl acetate, optionally wherein the acetyl donor is isopropenyl acetate. 
Postupak prema zahtjevu 10, pri čemu je acetil donor razgranati ili linearni C2-8 1-alkenil acetat, opcionalno gdje je acetil donor izopropenil acetat.
A process according to Claim 10, wherein the acetyl donor is acetic anhydride. 
Postupak prema zahtjevu 10, pri čemu acetil donor je anhidrid octene kiseline.
reducing the compound of formula IV obtained in step (a) to produce the compound of formula II 
redukciju spoja formule IV dobivenoga u koraku (a) da bi se proizveo spoj formule II
isolating a salt of formula I, as defined in Claim 1 or Claim 2, according to the process of any one of Claims 3 to 7, using the compound of formula II as formed in step (b); 
izoliranje soli formule I, kako je definirano u zahtjevu 1 ili zahtjevu 2, prema postupku bilo kojeg zahtjeva od 3 do 7 uz korištenje spoja formule II kako je dobiveno u koraku (b);
reacting the product obtained in step (c) with an acetyl donor, optionally in the presence of a base, to form Lacosamide; and 
reagiranje proizvoda dobivenoga u koraku (c) s acetil donorom, opcionalno u prisutnosti baze, da se dobije Lakozamid; i
crystallising the product obtained in step (d) in a suitable solvent. 
kristalizacija proizvoda dobivenoga u koraku (d) u odgovarajućem otapalu.
A method for preparing a penem antibiotic intermediate through a carbene insertion reaction, wherein under the catalysis of the supported rhodium catalyst according to claim 14, the penem antibiotic intermediate shown in formula (VI) is prepared by a compound shown in formula (V), and an equation of the reaction is as follows: wherein R2 is p-nitrobenzyl, 2-nitrobenzyl, 3-nitrobenzyl, benzyl, p -chlorobenzyl, p -methylbenzyl, allyl, methyl or ethyl, and R3 is hydrogen or methyl. 
Uporaba prema patentnom zahtjevu 8, naznačena time što se podržani rodijev katalizator upotrebljava za pripremu penem antibiotskog međuprodukta reakcijom umetanja karbena: pod katalizom podržanog rodijevog katalizatora penem antibiotski međuprodukt prikazan u formuli (VI) pripravljen je spojem prikazanim u formuli (V), i jednadžba reakcije je kako slijedi: pri čemu R2 je p-nitrobenzil, 2-nitrobenzil, 3-nitrobenzil, benzil, p-klorobenzil, p-metilbenzil, alil, metil ili etil, i R3 je vodik ili metil.
The method according to claim 17 or 18, wherein a molar ratio of the supported metal catalyst to the compound shown in formula (V) is 1:50∼2000. 
Uporaba prema patentnom zahtjevu 12 ili 13, naznačena time što molarni omjer podržanog metalnog katalizatora prema spoju prikazanom u formuli (V) iznosi 1:50 ∼ 2000.
The method of claim 43, wherein the disease, disorder, or medical condition is a mood disorder, post-traumatic stress disorder, a panic disorder, an attention deficit disorder, a cognitive deficiency, or substance abuse. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje poremećaj raspoloženja, posttraumatski stresni poremećaj, panični poremećaj, poremećaj nedostatka pozornosti, kognitivni nedostaci, ili zloupotreba opojnih sredstava.
The method of claim 43, wherein the disease, disorder, or medical condition is a sleep disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje poremećaj spavanja.
The method of claim 43, wherein the disease, disorder, or medical condition is a metabolic disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje metabolički poremećaj .
The method of claim 47, wherein the metabolic disorder is overweight, obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, or osteoarthritis. 
Farmaceutski sastav za upotrebu prema zahtjevu 7, gdje je metabolički poremećaj prekomjerna težina, pretilost, inzulinska rezistencija, dijabetes tipa II, hiperlipidemija, žučni kamenci, angina, hipertenzija, dispneja, tahikardija, neplodnost, apneja u snu, bol u leđima i zglobovima, proširene vene ili osteoartritis.
The method of claim 43, wherein the disease, disorder, or medical condition is a neurological disorder. 
Farmaceutski sastav za upotrebu prema zahtjevu 3, gdje je bolest, poremećaj ili medicinsko stanje, neurološki poremećaj.
The method of claim 49, wherein the neurological disorder is Parkinson's disease, Alzheimer's disease, Tourette's syndrome, catatonia, anxiety, delirium, or dementias. 
Farmaceutski sastav za upotrebu prema zahtjevu 9, gdje je neurološki poremećaj Parkinsonova bolest, Alzheimerova bolest, Touretteov sindrom, katatonija, anksioznost, delirij ili demencija.
Multi-outlet nozzle for electrohydrodynamic or aerohydrodynamic processing operations and which is of the type comprising at least one chamber for the flow of a fluid with: 
Mlaznica s više izlaza za elektrohidrodinamičku ili aerohidrodinamičku obradu i koja je vrste koja sadrži najmanje jednu komoru za protok tekućine sa:
A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji obuhvaća spoj sukladno zahtjevu 1 ili zahtjevu 2 i i farmaceutski prihvatljiv nosač.
reacting one or both hydroxyl groups in positions 5 and 20 of ingenol with suitable hydroxyl protecting agents, same or different, to obtain a compound of the general formula (III) or (IV) wherein R1 represents hydrogen or a hydroxyl protective group and R2 represents hydrogen or a hydroxyl protective group, with the proviso that not both R1 and R2 represent hydrogen, or wherein D represents a dihydroxyl protective group 
reagiranja jedne ili obje hidroksilne skupine u položajima 5 i 20 ingenola s odgovarajućim hidroksilnim zaštitnim sredstvima, istim ili različitim, da bi se dobio spoj opće formule (III) ili (IV) gdje R1 predstavlja vodik ili hidroksilnu zaštitnu skupinu i R2 predstavlja vodik ili hidroksilnu zaštitnu skupinu, uz uvjet da oba R1 i R2 ne predstavljaju vodik, ili gdje D predstavlja dihidroksilnu zaštitu skupinu
a mixed angelic acid anhydride; and 
mješovitim anhidridom angelinske kiseline; i
removing the hydroxyl protective groups R1 or R2, or R1 and R2, or D from compounds (V) or (VI) to obtain ingenol-3-angelate (I). 
uklanjanja hidroksilnih zaštitnih skupina R1 ili R2, ili R1 i R2, ili D iz spoja (V) ili (VI) da bi se dobio ingenol-3-angelat (I).
A method according to claim 1 wherein R1 represents hydrogen or an ether, acetal, ketal, silylether, ester, carbonate, or a sulfenate derived hydroxyl protective group, and R2 represents hydrogen or an ether, acetal, ketal, silylether, ester, carbonate, or a sulfenate derived hydroxyl protective group. 
Postupak prema zahtjevu 1, gdje R1 predstavlja vodik ili etersku, acetalnu, ketalnu, sililetersku, estersku, karbonatnu, ili sulfenatnu hidroksilnu zaštitnu skupinu i R2 predstavlja vodik ili etersku, acetalnu, ketalnu, sililetersku, estersku, karbonatnu, ili sulfenatnu hidroksilnu zaštitnu skupinu.
A method according to claim 1, 2 or 4 wherein R1 represents a hydroxyl protective group and R2 represents hydrogen. 
Postupak prema zahtjevu 1, 2 ili 4, gdje R1 predstavlja hidroksilnu zaštitnu skupinu i R2 predstavlja vodik.
A method according to claim 1, 2, 4 or 5, wherein step (b) comprises reacting compound (III) or (IV) with angelic acid anhydride: 
Postupak prema zahtjevu 1, 2, 4 ili 5, gdje korak (b) obuhvaća reagiranje spoja (III) ili (IV) s anhidridom angelinske kiseline:
without a catalyst; or 
bez katalizatora; ili
in a suitable solvent such as tetrahydrofuran, MeCN, pyridine or methyl tert-butyl ether. 
u odgovarajućem otapalu kao što je tetrahidrofuran, MeCN, piridin ili metil terc-butil eter.
in a suitable solvent such as toluene. 
u odgovarajućem otapalu kao što je toluen.
A method according to claim 1, 2, 3, 4, 5, 6, 7 or 8, wherein step (b) comprises reacting compound (III) or (IV) with angeloyl chloride. 
Postupak prema zahtjevu 1, 2, 3, 4, 5, 6, 7 ili 8, gdje korak (b) obuhvaća reagiranje spoja (III) ili (IV) s angeloil kloridom.
Solar cell module (1) comprising: 
Modul (1) solarne ćelije koji sadrži:
a first layer (7) having fields having a photovoltaic layer (8); 
prvi sloj (7) koji ima polja koja imaju fotonaponski sloj (8);
Solar cell module (1) according to claim 1, wherein the fields (9) having at least a reflective layer of the first layer (7) have a diamond or pyramid shaped relief. 
Modul (1) solarne ćelije u skladu sa patentnim zahtjevom 1, gdje polja (9) koja imaju barem reflektivni sloj prvog sloja (7) imaju reljef u obliku dijamanta ili piramide.
Solar cell module (1) according to claim 2, wherein the diamond or pyramid shaped relief is lined with pre-stretched graphene and wherein a layer of piezo-electric material (12) is arranged on the first layer (7) on the opposite side of the relief. 
Modul (1) solarne ćelije u skladu sa patentnim zahtjevom 2, gdje je reljef u obliku dijamanta ili piramide obložen prethodno istegnutim grafenom i gdje je sloj piezoelektričnog materijala (12) postavljen na prvom sloju (7) na suprotnoj strani reljefa.
Solar panel comprising a number of solar cell modules (1) according to the preceding claims, wherein the solar cell modules (1) are arranged electrically in series. 
Solarni panel koji sadrži veliki broj modula (1) solarnih ćelija u skladu sa prethodnim patentnim zahtjevima, gdje su moduli (1) solarnih ćelija električno raspoređeni u serijama.
A process of manufacturing apixaban tablets, wherein each tablet has a composition comprising up to 5 mg crystalline apixaban particles and a pharmaceutically acceptable diluent or carrier, comprising the steps of: 
Proces proizvodnje tableta apiksabana, pri čemu svaka tableta ima kompoziciju koja sadrži do 5 mg čestica kristalnog apiksabana i farmaceutski prihvatljiv razrjeđivač ili nosač, koji obuhvaća korake:
granulating the raw materials from step (1) using a dry granulation process, wherein the apixaban particles have a D90 less than 50 µm as measured by laser light scattering; 
granulacije sirovih materijala iz koraka (1) primjenom procesa suhe granulacije, pri čemu čestice apiksabana imaju D90 manji od 50 µm mjereno pomoću rasipanja laserske svjetlosti;
compacting the lubricated blend to ribbons of density in the range of 1.1 to 1.2 g/cm3 and size the compacted ribbons using a roller compactor; 
sabijanje ovlažene smjese u trake gustoće u opsegu od 1.1 do 1.2 g/cm3 i formiranje do date veličine sabijenih traka upotrebom valjak kompaktora;
granulating the raw materials from the step (1) using a dry granulation process; 
granulacije sirovih materijala iz koraka (1) primjenom procesa suhe granulacije;